ALZHEIMER'S DISEASE

  • Alzheimer’s disease is the most common age-related neurodegenerative disorder, characterized by the progressive degeneration of neuronal populations and the simultaneous loss of memory and cognitive functions.


    METHYLLYCACONITINE model

    Methyllycaconitine is an alpha-7 nicotinic acetylcholine receptor specific antagonist with brain penetrance. NEUROFIT has developed this model because these receptors play a central role in Alzheimer’s disease.

  • Compound testing


    Alpha-7 nicotinic acetylcholine receptor agonists or PAM alpha-7 are usually tested in this model but other treatments could also be considered. Please feel free to contact us to discuss the feasibility of your study.

  • Endpoints


    ☐ Percentage of alternation in the T-Maze (memory performance)
  • T-MAZE Continuous Alternation Task (T-CAT) in mice
  • Donepezil :

    Reversion of Methyllycaconitine-induced cognitive deficit in the T-Maze alternation task in the mouse

  • Memantine :

    Reversion of Methyllycaconitine-induced cognitive deficit in the T-Maze alternation task in the mouse



You could also be interested in



  • Scopolamine

    Scopolamine, a muscarinic receptor antagonist is widely used to induce cognitive / memory impairment in clinical research.

    Aged mice

    This model is probably the most representative of the human Alzheimer's disease.

  • Amyloid β : animal model

    Amyloid-β i.c.v injection induces learning deficits and a dysfunction of the cholinergic system.

    Amyloid β : cellular model

    Intoxication of neuronal cultures with Aβ has been widely used to understand some of the mechanisms of cell death in AD and thus represents an instrumental in-vitro system to evaluate the efficiency of new drug candidate.